South Korea · Delayed Price · Currency is KRW Cytogen Statistics
Total Valuation
Cytogen has a market cap or net worth of KRW 92.51 billion. The enterprise value is 83.35 billion.
| Market Cap | 92.51B |
| Enterprise Value | 83.35B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytogen has 23.07 million shares outstanding. The number of shares has increased by 1.14% in one year.
| Current Share Class | 23.07M |
| Shares Outstanding | 23.07M |
| Shares Change (YoY) | +1.14% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 27.14% |
| Owned by Institutions (%) | n/a |
| Float | 8.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.45 |
| PB Ratio | 2.71 |
| P/TBV Ratio | 3.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.45.
| Current Ratio | 3.44 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.60 |
| Interest Coverage | -2.94 |
Financial Efficiency
Return on equity (ROE) is -27.69% and return on invested capital (ROIC) is -8.17%.
| Return on Equity (ROE) | -27.69% |
| Return on Assets (ROA) | -7.06% |
| Return on Invested Capital (ROIC) | -8.17% |
| Return on Capital Employed (ROCE) | -15.76% |
| Weighted Average Cost of Capital (WACC) | 6.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.42 |
| Inventory Turnover | 6.48 |
Taxes
| Income Tax | -728.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.97% in the last 52 weeks. The beta is 0.16, so Cytogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +9.97% |
| 50-Day Moving Average | 4,725.90 |
| 200-Day Moving Average | 4,640.53 |
| Relative Strength Index (RSI) | 38.63 |
| Average Volume (20 Days) | 240,069 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cytogen had revenue of KRW 26.84 billion and -11.18 billion in losses. Loss per share was -484.91.
| Revenue | 26.84B |
| Gross Profit | 6.11B |
| Operating Income | -7.27B |
| Pretax Income | -11.91B |
| Net Income | -11.18B |
| EBITDA | -4.31B |
| EBIT | -7.27B |
| Loss Per Share | -484.91 |
Balance Sheet
The company has 25.01 billion in cash and 15.41 billion in debt, with a net cash position of 9.60 billion or 416.03 per share.
| Cash & Cash Equivalents | 25.01B |
| Total Debt | 15.41B |
| Net Cash | 9.60B |
| Net Cash Per Share | 416.03 |
| Equity (Book Value) | 34.11B |
| Book Value Per Share | 1,455.62 |
| Working Capital | 26.63B |
Cash Flow
In the last 12 months, operating cash flow was -7.68 billion and capital expenditures -1.93 billion, giving a free cash flow of -9.61 billion.
| Operating Cash Flow | -7.68B |
| Capital Expenditures | -1.93B |
| Depreciation & Amortization | 2.96B |
| Net Borrowing | -4.21B |
| Free Cash Flow | -9.61B |
| FCF Per Share | -416.40 |
Margins
Gross margin is 22.78%, with operating and profit margins of -27.08% and -41.68%.
| Gross Margin | 22.78% |
| Operating Margin | -27.08% |
| Pretax Margin | -44.38% |
| Profit Margin | -41.68% |
| EBITDA Margin | -16.05% |
| EBIT Margin | -27.08% |
| FCF Margin | n/a |
Dividends & Yields
Cytogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.14% |
| Shareholder Yield | -1.14% |
| Earnings Yield | -12.09% |
| FCF Yield | -10.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Sep 28, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Cytogen has an Altman Z-Score of 0.72 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.72 |
| Piotroski F-Score | 3 |